IRIS
BUTINI, STEFANIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 10.409
EU - Europa 10.187
AS - Asia 1.724
AF - Africa 60
SA - Sud America 22
OC - Oceania 20
Continente sconosciuto - Info sul continente non disponibili 11
Totale 22.433
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 10.348
GB - Regno Unito 2.995
IT - Italia 1.746
IE - Irlanda 1.552
CN - Cina 1.118
SE - Svezia 816
UA - Ucraina 728
RU - Federazione Russa 724
DE - Germania 630
FR - Francia 412
SG - Singapore 299
FI - Finlandia 269
TR - Turchia 132
ES - Italia 69
CA - Canada 56
CZ - Repubblica Ceca 47
CI - Costa d'Avorio 42
BE - Belgio 39
IN - India 37
AT - Austria 31
VN - Vietnam 24
GR - Grecia 23
IR - Iran 23
RO - Romania 22
AU - Australia 18
NL - Olanda 18
JP - Giappone 11
PT - Portogallo 11
EU - Europa 10
PL - Polonia 9
EG - Egitto 8
BR - Brasile 7
ID - Indonesia 7
KR - Corea 7
LV - Lettonia 7
SA - Arabia Saudita 7
CH - Svizzera 6
CL - Cile 6
IL - Israele 6
AZ - Azerbaigian 5
BD - Bangladesh 5
ZA - Sudafrica 5
BG - Bulgaria 4
DK - Danimarca 4
HK - Hong Kong 4
HU - Ungheria 4
LA - Repubblica Popolare Democratica del Laos 4
MA - Marocco 4
MY - Malesia 4
PA - Panama 4
PK - Pakistan 4
RS - Serbia 4
AE - Emirati Arabi Uniti 3
KG - Kirghizistan 3
KW - Kuwait 3
LT - Lituania 3
NO - Norvegia 3
PE - Perù 3
TH - Thailandia 3
AL - Albania 2
AR - Argentina 2
BO - Bolivia 2
BY - Bielorussia 2
EE - Estonia 2
GE - Georgia 2
HR - Croazia 2
KZ - Kazakistan 2
LK - Sri Lanka 2
NZ - Nuova Zelanda 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AM - Armenia 1
CO - Colombia 1
EC - Ecuador 1
IM - Isola di Man 1
IQ - Iraq 1
IS - Islanda 1
JM - Giamaica 1
JO - Giordania 1
KH - Cambogia 1
MC - Monaco 1
NG - Nigeria 1
SY - Repubblica araba siriana 1
TJ - Tagikistan 1
TM - Turkmenistan 1
TW - Taiwan 1
UZ - Uzbekistan 1
Totale 22.433
Salva come PNG Salva come JPEG
Città #
Southend 2.794
Fairfield 1.754
Dublin 1.537
Ashburn 1.068
Woodbridge 788
Chandler 787
Siena 722
Seattle 653
Wilmington 642
Cambridge 602
Jacksonville 602
Houston 601
Ann Arbor 443
Princeton 264
Beijing 255
Singapore 245
Nanjing 209
Dearborn 146
Helsinki 116
Fremont 115
Izmir 114
New York 112
Boardman 106
Florence 106
Shanghai 97
San Diego 87
San Mateo 84
Washington 79
Nanchang 74
Moscow 65
Málaga 56
Rome 51
Lancaster 49
Hebei 46
Milan 46
Lappeenranta 45
Abidjan 42
Brno 42
Shenyang 40
Jiaxing 38
Redwood City 35
Aachen 34
Brussels 34
Jinan 33
Kunming 33
Düsseldorf 31
London 31
Norwalk 31
Tianjin 31
Los Angeles 30
Venezia 30
Changsha 27
Menlo Park 26
Guangzhou 25
Ningbo 25
Ottawa 25
Munich 24
Vienna 24
Dong Ket 23
San Francisco 22
Toronto 20
Turin 17
Hangzhou 16
Hefei 16
Parma 15
Pisa 15
Prato 15
Avellino 14
Frankfurt am Main 14
Timisoara 14
Marietta 12
Zhengzhou 12
Columbus 11
Salerno 11
San Giovanni Valdarno 11
Palermo 10
Changchun 9
Fisciano 9
Hanover 9
Lastra a Signa 9
Maletto 9
Mestre 9
Naples 9
Philadelphia 9
Arezzo 8
Borgo San Lorenzo 8
Catanzaro 8
Palo Alto 8
Taizhou 8
Ventimiglia 8
Bari 7
Bologna 7
Lanuvio 7
Padova 7
Riga 7
Santa Clara 7
Tokyo 7
Catania 6
Dallas 6
Lanzhou 6
Totale 16.706
Salva come PNG Salva come JPEG
Nome #
Development of Potent Inhibitors of the Mycobacterium tuberculosis Virulence Factor Zmp1 and Evaluation of Their Effect on Mycobacterial Survival inside Macrophages 294
Development of novel cyclic peptides as pro-apoptotic agents 273
Structure-activity relationships, biological evaluation and structural studies of novel pyrrolonaphthoxazepines as antitumor agents 270
Antimalarial agents against both sexual and asexual parasites stages: structure-activity relationships and biological studies of the Malaria Box compound 1-[5-(4-bromo-2-chlorophenyl)furan-2-yl]- N -[(piperidin-4-yl)methyl]methanamine (MMV019918) and analogues 263
(S)-2-Amino-3-(5-methyl-3-hydroxyisoxazol-4-yl)propanoic Acid (AMPA) and Kainate Receptor Ligands: further exploration of bioisosteric replacements and structural and biological investigation 257
iPSC-derived neurons profiling reveals GABAergic circuit disruption and acetylated α-tubulin defect which improves after iHDAC6 treatment in Rett syndrome 250
Development and Pharmacological Characterization of Selective Blockers of 2-Arachidonoyl Glycerol Degradation with Efficacy in Rodent Models of Multiple Sclerosis and Pain 249
Novel spiroindoline HDAC inhibitors: Synthesis, molecular modelling and biological studies 230
Synthetic spirocyclic endoperoxides: new antimalarial scaffolds 227
A new microtubule-targeting compound PBOX-15 inhibits T-cell migration via post-translational modifications of tubulin 222
The 1-(2,3-dichlorophenyl)-piperazine-to-aripiprazole ratio at steady state in rats and schizophrenic patients 220
First dual AK/GSK-3β inhibitors endowed with antioxidant properties as multifunctional, potential neuroprotective agents 216
Bridged bicyclic 2,3-dioxabicyclo[3.3.1]nonanes as antiplasmodial agents: Synthesis, structure-activity relationships and studies on their biomimetic reaction with Fe(II) 215
Development of Potent Inhibitors of Fatty Acid Amide Hydrolase Useful for the Treatment of Neuropathic Pain 213
Development of novel multipotent compounds modulating endocannabinoid and dopaminergic systems 212
Natural Compounds and Synthetic Drugs to Target FAAH Enzyme 212
Synthesis, Molecular Modelling and Biological Studies of 3-hydroxy-pyrane-4-one and 3-hydroxy-pyridine-4-one Derivatives as HIV-1 Integrase Inhibitors 211
Old but gold: tracking the new guise of Histone Deacetylase 6 (HDAC6) enzyme as a biomarker and therapeutic target in rare diseases 211
Targeting Dopamine D3and Serotonin 5-HT1Aand 5-HT2AReceptors for Developing Effective Antipsychotics: Synthesis, Biological Characterization, and Behavioral Studies 200
Identification of novel fluorescent probes preventing PrP(Sc) replication in prion diseases 199
A Jocic-type approach for a practical and scalable synthesis of pyrrolonaphthoxazepine (PNOX)-based potent proapoptotic agents 199
Activation of the Wnt pathway by small peptides: rational design, synthesis and biological evaluation 198
Structure-based discovery of the first non-covalent inhibitors of Leishmania major tryparedoxin peroxidase by high throughput docking 197
null 195
Discovery of a new class of potential multifunctional atypical antipsychotic agents targeting dopamine d3 and serotonin 5-HT 1A and 5-HT2A receptors: Design, synthesis, and effects on behavior 188
Structural characterization of Giardia duodenalis thioredoxin reductase (gTrxR) and computational analysis of its interaction with NBDHEX 186
Targeting clinically-relevant metallo-β-lactamases: from high-throughput docking to broad-spectrum inhibitors 185
Selective Kainate Receptor (GluK1) Ligands Structurally Based upon 1H-Cyclopentapyrimidin-2,4(1H,3H)-dione: Synthesis, Molecular Modeling, and Pharmacological and Biostructural Characterization 184
A stereoselective route to 6-substituted pyrrolo-1,5-benzoxazepinones and their analogues 183
1H-Cyclopentapyrimidine-2,4(1H,3H)-dione-Related Ionotropic Glutamate Receptors Ligands. Structure-Activity Relationships and Identification of Potent and Selective iGluR5 Modulators 180
Optimization of 4-Aminoquinoline/Clotrimazole-Based Hybrid Antimalarials: Further Structure-Activity Relationships, in vivo Studies, and Preliminary Toxicity Profiling 178
Multitarget compounds bearing tacrine- and donepezil-like structural and functional motifs for the potential treatment of Alzheimer's disease 174
Synthetic studies toward 1,2-dioxanes as precursors of potential endoperoxide-containing antimalarials 173
Telomerase-based cancer therapeutics: a review on their clinical trials 173
The FAAH inhibitor URB597 suppresses hippocampal maximal dentate afterdischarges and restores seizure-induced impairment of short and long-term synaptic plasticity 171
Discovery of Potent Inhibitors of Human and Mouse Fatty Acid Amide Hydrolases 171
Non-Nucleoside Inhibitors of Human Adenosine Kinase: Synthesis, Molecular Modeling, and Biological Studies 169
Pyrrolo 1,3 benzothiazepine-based Atypical Antipsychotic Agents. Synthesis, Structure-Activity Relationship, Molecular Modeling, and Biological Studies 169
A light in the dark: State of the art and perspectives in optogenetics and optopharmacology for restoring vision 169
Discovery of Bishomo(hetero)arylpiperazines as Novel Multifunctional Ligands Targeting Dopamine D-3 and Serotonin 5-HT1A and 5-HT2A Receptors 168
Synthesis and Antiplasmodial Activity of Bicyclic Dioxanes as Simplified Dihydroplakortin Analogues 166
Exploiting Protein Fluctuations at the Active-Site Gorge of Human Cholinesterases: Further Optimization of the Design Strategy to Develop Extremely Potent Inhibitors 165
Design and Synthesis of Potent Antimalarial Agents Based on Clotrimazole Scaffold: Exploring an Innovative Pharmacophore 165
Mimicking the Intramolecular Hydrogen Bond: Synthesis, Biological Evaluation, and Molecular Modeling of Benzoxazines and Quinazolines as Potential Antimalarial Agents 165
Synthesis and structure–activity relationship studies in serotonin 5-HT1A receptor agonists based on fused pyrrolidone scaffolds 165
Microwave-assisted synthesis of 4-quinolylhydrazines followed by nickel boride reduction: a convenient approach to 4-aminoquinolines and derivatives 164
A synthetic strategy to bridged 2,3,8-trioxabicyclo[3,3,1]nonane endoperoxides 164
Synthesis of Dihydroplakortin, 6-epi-Dihydroplakortin, and Their C10-Desethyl Analogues 163
The Interactions of the 5-HT3 Receptor with Quipazine-Like Arylpiperazine Ligands. The Journey Track at the End of the First Decade of the Third Millennium 162
A stereoselective approach to peptidomimetic BACE1 inhibitors 162
Unravelling the response of chronic lymphocytic leukemia to a novel class of anticancer agents, the pyrrolonaphthoxazepines (PNOXs) 162
Quinolylhydrazones as novel inhibitors of Plasmodium falciparum serine protease PfSUB1 160
Synthetic studies toward bicyclic endoperoxides presenting polar side chains 160
Novel quinolone-based potent and selective HDAC6 inhibitors: synthesis, molecular modeling studies and biological investigation 159
Pyrroloquinoxaline Derivatives as High-Affinity and Selective 5-HT3 Receptor Agonists: Synthesis, Further Structure-Activity Relationships, and Biological Studies 157
Donepezil-like multifunctional agents: Design, synthesis, molecular modeling and biological evaluation 157
Endocannabinoid Modulation of Predator Stress-Induced Long-Term Anxiety in Rats 156
Dopamine D3 receptor antagonists as potential therapeutics for the treatment of neurological diseases 156
Novel peptidomimetics as BACE-1 inhibitors: synthesis, molecular modeling, and biological studies 154
Development of a multiplexed activity-based protein profiling assay to evaluate activity of endocannabinoid hydrolase inhibitors 153
ARYL PIPERAZINE DERIVATIVES USEFUL FOR THE TREATMENT OF NEUROPSYCHIATRY DISORDERS. 152
Synthesis of N1-arylidene-N2-quinolyl- and N2-acrydinylhydrazones as potent antimalarial agents active against CQ-resistant P. falciparum strains 152
Development of piperazine-tethered heterodimers as potent antimalarials against chloroquine-resistant P. falciparum strains. Synthesis and molecular modeling 152
Development of Antitubercular Compounds Based on a 4-Quinolylhydrazone Scaffold. Further Structure-activity Relationship Studies 151
Design, synthesis, and structure-activity relationship studies of 4-quinolinyl- and 9-acrydinylhydrazones as potent antimalarial agents 151
Azetidin-2-one-based small molecules as dual hHDAC6/HDAC8 inhibitors: Investigation of their mechanism of action and impact of dual inhibition profile on cell viability 151
Raising the bar in anticancer therapy: recent advances in, and perspectives on, telomerase inhibitors 150
A palladium-catalyzed synthetic approach to new Huperzine A analogues modified at the pyridone ring 148
Allosteric Modulation of Ionotropic Glutamate Receptors: An Outlook on New Therapeutic Approaches To Treat Central Nervous System Disorders 148
Selective Fatty Acid Amide Hydrolase Inhibitors as Potential Novel Antiepileptic Agents 147
Development of molecular probes for the identification of extra interaction sites in the mid-gorge and peripheral sites of butyrylcholinesterase (BuChE). Rational design of novel, selective, and highly potent BuChE inhibitors 146
Malaria chemotherapy: recent advances in drug development 145
Novel aryl piperazine derivatives with medical utility 143
Multifunctional Cholinesterase and Amyloid Beta Fibrillization Modulators. Synthesis and Biological Investigation 143
Pyrroloquinoxaline hydrazones as fluorescent probes for amyloid fibrils 142
Harnessing the role of HDAC6 in Idiopathic Pulmonary Fibrosis: design, synthesis, structural analysis, and biological evaluation of potent inhibitors 142
Pyrrolo[1,5]benzoxa(thia)zepines as a New Class of Potent Apoptotic Agents. Biological Studies and Identification of an Intracellular Location of Their Drug Target 141
Specific Targeting of Hepatitis C Virus NS3 RNA Helicase. Discovery of the Potent and Selective Competitive Nucleotide-Mimicking Inhibitor QU663 141
Discovery of Huperzine A/Tacrine Hybrids as Potent Inhibitors of Human Cholinesterases Targeting Their Mid-gorge Recognition Sites 137
A Straightforward Approach for Engineering Efficacy and Selectivity at GPCRs 136
Identification of a novel arylpiperazine scaffold for fatty acid amide hydrolase inhibition with improved drug disposition properties 136
Specific Targeting of Peripheral Serotonin 5-HT3 Receptors. Synthesis, Biological Investigation and Structure Activity Relationships 136
Computational tool for fast in silico evaluation of hERG K+ channel affinity 135
Retinitis pigmentosa and retinal degenerations: deciphering pathways and targets for drug discovery and development 135
Disease modifying anti-Alzheimer’s drugs: inhibitors of human cholinesterases interfering with β-amyloid aggregation 132
Site-directed mutagenesis of key residues unveiled a novel allosteric site on human adenosine kinase for Pyrrolobenzoxa(thia)zepinone non-nucleoside inhibitors 132
COMPOUNDS WITH ATYPICAL ANTIPSYCHOTIC ACTIVITY 131
Specific Targeting of Highly Conserved Residues in the HIV-1 Reverse Transcriptase Primer Grip Region. 2. Stereoselective Interaction to Overcome the Effects of Drug Resistant Mutations 131
An efficient approach to chiral C8/C9-Piperazino-Substituted 1,4-Benzodiazepin-2-ones as peptidomimetic scaffolds 129
Neuronal high affinity sodium-dependent glutamate transporters (EAATs): targets for the development of novel therapeutics against neurodegenerative diseases 129
The Ca2+-ATPase (SERCA1) Is Inhibited by 4-Aminoquinoline Derivatives through Interference with Catalytic Activation by Ca2+, Whereas the ATPase E2 State Remains Functional 127
Screening and phenotypical characterization of Schistosoma mansoni Histone Deacetylase 8 (SmHDAC8) inhibitors as multistage antischistosomal agents 127
Rational design of the first difluorostatone-based PfSUB1 inhibitors 126
CARBAMATE DERIVATIVES IN PARTICULAR FOR THE TREATMENT OF NEUROLOGICAL DISORDERS 126
Phenylpyrrole-based HDAC inhibitors: synthesis, molecular modeling and biological studies 125
Harnessing the pyrroloquinoxaline scaffold for FAAH and MAGL interaction: definition of the structural determinants for enzyme inhibition 125
Identification of novel 3-Hydroxy-pyran-4-one derivatives as potent HIV-1 integrase inhibitors using in silico structure-based combinatorial library design approach 124
Enantioselective binding of second generation pyrrolobenzoxazepinones to the catalytic ternary complex of HIV-1 RT wild-type and L100I and K103N drug resistant mutants 123
'Polycondensed heterocycles. Part 12: an approach to the synthesis of 2-acetyl-1'-methyl-1,2,3,4-tetrahydrospiro[isoquinoline-1,4'-pyrrolidine]-2'-one 123
Novel atypical antipsychotic agents: rational design, an efficient palladium-catalyzed route, and pharmacological studies 121
Totale 16.960
Salva come PNG Salva come JPEG
Categoria #
all - tutte 71.938
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 71.938
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20202.815 0 0 0 0 309 426 402 513 379 399 119 268
2020/20214.033 161 338 204 358 263 609 331 463 322 475 317 192
2021/20222.602 229 307 226 156 123 73 133 111 123 330 294 497
2022/20233.081 178 302 415 392 337 602 89 242 277 100 93 54
2023/20242.984 107 55 276 137 183 797 895 42 30 99 124 239
2024/20251.470 165 223 658 303 121 0 0 0 0 0 0 0
Totale 22.946